Drug Trial Radar · NCT05047263
A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease
Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,584
Actual
Start
Sep 21, 2021
Primary completion
Dec 31, 2025
Study completion Feb 2, 2026
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Sep 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certain hormone called aldosterone that causes injury and inflammation in the heart and kidney which is known to play a role in CKD. In this trial, the researchers want to learn if finerenone helps to slow down the worsening of the participants' non-diabetic CKD compared to a placebo. A placebo looks like a trial treatment but does not have any medicine in it. The trial will include about 1,580 men and women who are at least 18 years old. The participants will take finerenone or a placebo once a day as tablets by mouth. All of the participants will also continue to take their current medicine for their CKD. The participants will be in the trial for up to about 50 months. During the trial, the doctors will collect blood and urine samples and check the participants' health. The participants will also answer questions about how they are feeling and what adverse events they are having. An adverse event is a medical problem that happens during the trial. Doctors keep track of all adverse events that happen in trials, even if they do not think the adverse events might be related to the trial treatments.
Conditions
- Non-diabetic Chronic Kidney Disease
Interventions
Finerenone (BAY94-8862)Drug
Tablet, 10 mg or 20 mg, once daily (OD), oral
PlaceboDrug
Tablet, once daily, oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean rate of change as measured by the total slope of eGFR from baseline to Month-32.Time frame: From baseline to month 32
Locations
326 sites in 24 countries. Site status is shown where the registry gives one.
Nephrology Consultants, LLC
Huntsville, Alabama
Balboa Research SMO+ - Chula Vista - West
Chula Vista, California
Balboa Research SMO+ - El Centro
El Centro, California
UCLA Clinical and Translational Research Center - Nephrology
Los Angeles, California
Balboa Nephrology Medical Group - Poway
Poway, California
North America Research Institute - San Dimas
San Dimas, California
United Clinical Research & Innovations
South Gate, California
University of Colorado | Renal Research Office
Aurora, Colorado
DaVita Clinical Research | Middlebury, CT
Middlebury, Connecticut
Yale University | Nephrology Clinical Research
New Haven, Connecticut
Chase Medical Research, LLC
Waterbury, Connecticut
Research Physicians Network Alliance
Boca Raton, Florida
Florida Kidney Physicians - Boca Raton
Boca Raton, Florida
AdventHealth Translational Research Institute
Orlando, Florida
Grady Memorial Hospital - Endocrinology
Atlanta, Georgia
Southeastern Clinical Research Institute, LLC
Augusta, Georgia
Central Georgia Kidney Specialists - Macon
Macon, Georgia
Frenova Renal Research | Boise Kidney and Hypertension
Meridian, Idaho
Northwestern Medicine - Feinberg School of Medicine - Nephrology and Hypertension
Chicago, Illinois
Research by Design, LLC | Chicago, IL
Chicago, Illinois
Nephrology Associates of Northern Illinois and Indiana - Hinsdale
Hinsdale, Illinois
University of Iowa Health Care Medical Center - Cardiology
Iowa City, Iowa
KUMC Clinical and Translational Science Unit - Nephrology
Kansas City, Kansas
Kansas Nephrology Research Institute
Wichita, Kansas
Wichita Nephrology Group, PA
Wichita, Kansas
Northwest Louisiana Nephrology - Shreveport - 1800 Buckner St.
Shreveport, Louisiana
Johns Hopkins Hospital - Nephrology
Baltimore, Maryland
Tufts Medical Center | Nephrology Department
Boston, Massachusetts
DaVita Clinical Research | Edina, MN
Edina, Minnesota
University Hospital - UMMC - Nephrology
Jackson, Mississippi
Clinical Research Consultants, a JCCT Company
Kansas City, Missouri
St. Louis Heart and Vascular, PC - Christian Hospital Office
St Louis, Missouri
UNM Clinical and Translational Science Center - Nephrology
Albuquerque, New Mexico
Mountain Kidney & Hypertension Associates
Asheville, North Carolina
UNC Hospitals Outpatient Center at Eastowne - Nephrology
Chapel Hill, North Carolina
East Carolina University | Nephrology & Hypertension
Greenville, North Carolina
Eastern Nephrology Associates | Wilmington
Wilmington, North Carolina
UH Cleveland Medical Center - Nephrology
Cleveland, Ohio
Cleveland Clinic | Urological and Kidney Department
Cleveland, Ohio
Northeast Clinical Research Center | Bethlehem, PA
Bethlehem, Pennsylvania
Showing 40 of 326 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.